Heterogeneous cell population

This target designation refers to therapeutic interventions, primarily cell-based therapies like mesenchymal stem cells (MSCs), that do not rely on a single molecular interaction but rather on the collective activity of a heterogeneous cell population. These cells function as dynamic sensors of the environment, migrating to sites of injury or inflammation where they exert effects through paracrine signaling and direct cell-cell interactions (Pittenger et al., 2019). The secretome of these cells—comprising cytokines, chemokines, and exosomes—modulates the host immune system and promotes endogenous tissue regeneration (Vizoso et al., 2017). Because the therapeutic effect is mediated by a complex mixture of factors rather than a discrete protein, this target represents a shift from the traditional one drug, one target paradigm to a systems-biology approach in regenerative medicine. This complexity poses unique challenges for drug development, particularly in defining potency assays and ensuring product consistency across different donors and manufacturing processes (Galipeau & Sensébé, 2018). Consequently, while these populations are listed as targets in some pharmacological contexts, they are more accurately described as therapeutic modalities that interact with the host microenvironment (Caplan, 2017).

Other names

No specific molecular target – heterogeneous cell population acting via paracrine signaling and cell–cell interactionsCell-based therapyMesenchymal stromal cell therapyMedicinal signaling cellsMultipotent stromal cellsParacrine-acting cell population

Modulation of the immune microenvironment and promotion of tissue repair through the secretion of a complex secretome (cytokines, growth factors, exosomes) and direct physical interaction with host immune cells.